Drug Trial Radar · NCT06419205
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- Akebia TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
Conditions
- IgA Nephropathy
- Lupus Nephritis (LN)
- C3 (Complement Component 3) Glomerulopathy
Interventions
ADX-097Drug
Subcutaneous Infusions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants reporting treatment emergent adverse events (TEAEs)Time frame: Up to 30 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Investigator Site #3
Hollywood, Florida · Recruiting
Investigator Site #1
Lawrenceville, Georgia · Recruiting
Investigator Site #4
Orangeburg, South Carolina · Recruiting
Investigator Site #2
São Paulo, Brazil · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.